The PE Ratio as of July 2024 (TTM) for Ionis Pharmaceuticals, Inc. (IONS) is -19.27

According to Ionis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -19.27. This represents a change of -67.36% compared to the average of -59.03 of the last 4 quarters.

Ionis Pharmaceuticals, Inc. (IONS) Historical PE Ratio (quarterly & annually)

How has IONS PE Ratio performed in the past?

The mean historical PE Ratio of Ionis Pharmaceuticals, Inc. over the last ten years is -153.06. The current -19.27 PE Ratio has changed 1.16% with respect to the historical average. Over the past ten years (40 quarters), IONS's PE Ratio was at its highest in in the December 2017 quarter at 572.01. The PE Ratio was at its lowest in in the June 2019 quarter at -2272.00.

Ionis Pharmaceuticals, Inc. (IONS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Ionis Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ionis Pharmaceuticals, Inc. (IONS) Average PE Ratio

How has IONS PE Ratio performed in the past?

The current PE Ratio of Ionis Pharmaceuticals, Inc. (IONS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Ionis Pharmaceuticals, Inc. (IONS) PE Ratio vs. Peers

How is IONS’s PE Ratio compared to its peers?

Ionis Pharmaceuticals, Inc.’s PE Ratio is less than Arrowhead Pharmaceuticals, Inc. (0), less than BioMarin Pharmaceutical Inc. (-7.38), less than Incyte Corporation (77.76), less than Apellis Pharmaceuticals, Inc. (20.66), less than Viking Therapeutics, Inc. (-11.71), greater than Intercept Pharmaceuticals, Inc. (-75.29), less than Terns Pharmaceuticals, Inc. (-13.55), less than Akero Therapeutics, Inc. (-7.36), less than Reata Pharmaceuticals, Inc. (-9.30), greater than Seagen Inc. (-89.36), greater than Alnylam Pharmaceuticals, Inc. (-57.36), greater than Exelixis, Inc. (-89.20), less than Halozyme Therapeutics, Inc. (34.31), less than PTC Therapeutics, Inc. (22.39), less than Krystal Biotech, Inc. (-4.50), less than Sarepta Therapeutics, Inc. (105.76), less than Iovance Biotherapeutics, Inc. (802.35), less than Madrigal Pharmaceuticals, Inc. (-5.48), less than null (-12.81),

Build a custom stock screener for Ionis Pharmaceuticals, Inc. (IONS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ionis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ionis Pharmaceuticals, Inc. (IONS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ionis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.